CD133在肺癌中的研究与进展

Research and advance of CD133 in lung cancer

肺癌是世界范围内死亡率最高的恶性肿瘤之一，也是我国常见的恶性肿瘤之一，恶性程度高，发展迅速，治疗困难，总体疗效不理想。肿瘤干细胞是肿瘤组织中一小部分具有自我更新、无限增殖和多向分化能力的肿瘤细胞，它在肿瘤组织中所占比例虽然很少，却与肿瘤起源、发展与转移关系密切，因此肿瘤干细胞被看作是一个根除癌症的潜在目标。CD133是在人类造血干细胞中发现的一种跨膜糖蛋白，并认为是多种干细胞的表面标志之一，并且CD133＋细胞与肿瘤的转移、肿瘤的血管生成都有关系。另外研究者报道，可通过检测CD133mRNA水平预测肿瘤的复发，并且认为可以作为某些肿瘤的预后指标。因此，有人认为CD133可能是肺癌干细胞的肿瘤标记物。本文就CD133在肺癌中的研究加以综述。

Lung carcinoma is one of the most common cause of cancer-related death in the world, and is also one of the most common malignant tumors in China. It is difficult to cure because of its high- grade malignancy and rapid progress. Cancer stem cells （CSC） is a small part of tumor cells with selfrenewal, unlimited proliferation and multi-differentiatlon capacity in tumor tissue. While CSC has small proportion in the tumor tissue, it is closely related with tumor origin, development and metastasis, and thus considered as a potential target to eradicate tumors. CD133 is a transmembrane glycoprotein found in human hematopoietic stem cells, which is thought as a surface marker of several stem cells. CD133＋ cells are associated with tumor metastasis and tumor microvessels formation. Tumor relapse could be detected by quantitative CD133 mRNA expression. CD133 is also the biomarker of CSC of lung cancer. So this paper reviews CD133 and the related research in lung cancer.